It is increasingly recognized that the natural history of cancer formation is a complex path taking many years to develop to a clinically apparent stage in most cases. However, with advancing knowledge comes a whole plethora of questions explored in this book.
It is increasingly recognized that the natural history of cancer formation is a complex path taking many years to develop to a clinically apparent stage in most cases. However, with advancing knowledge comes a whole plethora of questions explored in this book.
The need for new agents.- Identifying pre-clinical agents.- Pre-clinical evaluation.- Design of early phase trials.- Strategies for trial design and analyses.- Overview on Molecular and Animal models of ALL.- Apoptosis, BCL2.- Targeting Stem Cells.- Nucleoside Analogues.- Flt3 Inhibitors.- Tyrosine Kinase Inhibitors.- Monoclonal Antibodies.- Proteasome inhibitors.- Targeting epigenetic pathways in ALL.- Incorporating new therapies in frontline protocols.-
The need for new agents.- Identifying pre-clinical agents.- Pre-clinical evaluation.- Design of early phase trials.- Strategies for trial design and analyses.- Overview on Molecular and Animal models of ALL.- Apoptosis, BCL2.- Targeting Stem Cells.- Nucleoside Analogues.- Flt3 Inhibitors.- Tyrosine Kinase Inhibitors.- Monoclonal Antibodies.- Proteasome inhibitors.- Targeting epigenetic pathways in ALL.- Incorporating new therapies in frontline protocols.-
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
